Docetaxel, Bevacizumab with ADT May Produce PSA Response

Share this content:
Docetaxel with bevacizumab as well as ADT produces PSA response in prostate cancer with biochemical recurrence.
Docetaxel with bevacizumab as well as ADT produces PSA response in prostate cancer with biochemical recurrence.

Docetaxel with bevacizumab as well as androgen deprivation therapy (ADT) is feasible and produces PSA response in men with prostate cancer who experience biochemical recurrence, according to a study published online ahead of print in Cancer.

Researchers led by Rana McKay, MD, of the Dana-Farber Cancer Institute looked at 41 patients who had increasing PSA levels, PSA doubling time of at least 10 months, and no evidence of metastases after radical prostatectomy and/or radiotherapy.

Patients were given ADT for 18 months as well as docetaxel every three weeks for four cycles and bevacizumab every three weeks for eight cycles.

Primary endpoint was number of patients who were PSA progression-free after one year of therapy.

The researchers found that, after one year of completion of ADT, 45 percent of patients with testosterone levels of at least 100 ng/dL and 29 percent of patients with testosterone levels of at least 240 ng/dL had PSA of less than 0.2 ng/mL.

RELATED: Role of Genetic Mutations in Metastatic Castrate-Resistant Prostate Cancer Treatment

Additionally, eight patients (20 percent) were free from PSA progression, 19 patients (46 percent) did not reinitiate ADT, and 34 patients (83 percent) were free from metastasis.

However, 16 patients (39 percent) experienced grade 3 and 5 patients (12 percent) experienced grade 4 toxicities.

“Long-term follow-up is needed to determine the percentage of patients with a durable PSA response who are able to avoid having to reinitiate prostate cancer therapy,” the authors concluded.

Reference

  1. McKay, R. R., Gray, K. P., Hayes, J. H., Bubley, G. J., Rosenberg, J. E., Hussain, A., Kantoff, P. W. and Taplin, M.-E. (2015), Docetaxel, bevacizumab, and androgen deprivation therapy for biochemical disease recurrence after definitive local therapy for prostate cancer. Cancer. doi: 10.1002/cncr.29398

Related Resources

You must be a registered member of Cancer Therapy Advisor to post a comment.

Regimen and Drug Listings

GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION

Bone Cancer Regimens Drugs
Brain Cancer Regimens Drugs
Breast Cancer Regimens Drugs
Endocrine Cancer Regimens Drugs
Gastrointestinal Cancer Regimens Drugs
Gynecologic Cancer Regimens Drugs
Head and Neck Cancer Regimens Drugs
Hematologic Cancer Regimens Drugs
Lung Cancer Regimens Drugs
Other Cancers Regimens
Prostate Cancer Regimens Drugs
Rare Cancers Regimens
Renal Cell Carcinoma Regimens Drugs
Skin Cancer Regimens Drugs
Urologic Cancers Regimens Drugs

Sign Up for Free e-newsletters